Zacks: Analysts Anticipate Achillion Pharmaceuticals, Inc. (ACHN) to Announce -$0.15 Earnings Per Share

Wall Street analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will report ($0.15) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.15). Achillion Pharmaceuticals reported earnings of ($0.17) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 11.8%. The business is scheduled to report its next quarterly earnings results on Thursday, February 28th.

On average, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.50). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.60) to ($0.52). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02.

Separately, BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $4.38.

Several large investors have recently made changes to their positions in ACHN. Acadian Asset Management LLC bought a new position in shares of Achillion Pharmaceuticals during the second quarter valued at $135,000. Cubist Systematic Strategies LLC bought a new position in shares of Achillion Pharmaceuticals during the second quarter valued at $147,000. BlueMountain Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the second quarter valued at $159,000. Logan Capital Management Inc. bought a new position in Achillion Pharmaceuticals in the third quarter valued at about $166,000. Finally, MetLife Investment Advisors LLC lifted its holdings in Achillion Pharmaceuticals by 81.0% in the third quarter. MetLife Investment Advisors LLC now owns 101,528 shares of the biopharmaceutical company’s stock valued at $374,000 after acquiring an additional 45,425 shares during the period. 77.61% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:ACHN traded up $0.05 during midday trading on Friday, reaching $2.89. 770,170 shares of the company’s stock traded hands, compared to its average volume of 1,517,464. The company has a market cap of $393.67 million, a P/E ratio of -4.66 and a beta of 1.69. Achillion Pharmaceuticals has a one year low of $2.33 and a one year high of $4.34.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Recommended Story: Earnings Per Share (EPS) Explained

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit